Recent Updates
Recently added Catalysts
Biotech Catalyst Screener
| Company | Price | Drug | Phase | Completion Date | Status | PTRS | Condition | Trial Change | Design | ML Signal | Market Cap | Cash | Runway | Burn Rate | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 BMRNBioMarin Pharmaceutical Inc. | 65.63 0.23 % | PHASE3 | 2026-08-01 Updated 3mo ago | Active | 53% | LOW | C (59) | Moderate | 12.71 B | 874.00 | 30.51 | 72.85 M | PROFITABLE | ||
 BMYBristol-Myers Squibb Company | 63.41 -0.53 % | PHASE2 | 2026-08-01 Updated 3mo ago | Active | 34% | LOW | B (63) | Moderate | 129.57 B | 11.46 K | - | - | PROFITABLE | ||
 NVONovo Nordisk A/S | 42.945 -2.42 % | Semaglutide Pen Injector, Placebo Accelerated | PHASE2 | 2026-08-01 Updated 3mo ago | Recruiting | 21% | MEDIUM | — | ELEVATED_RISK | 145.70 B | 4.16 B | - | - | PROFITABLE | |
 TMDXTransMedics Group, Inc. | 81.06 -4.68 % | — | 2026-08-01 Updated 3mo ago | Active | — | LOW | D (23) | — | 2.80 B | 472.68 | 25.16 | 18.35 M | PROFITABLE | ||
 ZBHZimmer Biomet Holdings, Inc. | 92.815 0.39 % | — | 2026-08-01 Updated 3mo ago | Recruiting | — | LOW | F (17) | — | 17.70 B | 410.00 | 3.04 | 139.47 M | PROFITABLE | ||
 AMGNAmgen Inc. | 379.165 -0.87 % | PHASE2 | 2026-08-01 Updated 3mo ago | Not Yet Recruiting | 19% | LOW | — | — | 205.12 B | 27.40 K | - | - | PROFITABLE |
Biotech catalyst screener: frequently asked questions
What is a biotech catalyst screener?
A biotech catalyst screener filters upcoming biotech catalysts, clinical trial data readouts, trial completions, and FDA regulatory events by company and trial attributes. Catalyst Sync screens 11,000+ catalysts across 949 biotech companies by cash runway, burn rate, trial phase, therapeutic area, FDA designation, and PTRS approval probability.
How do I find biotech companies with low cash runway and an upcoming catalyst?
Set the Runway or Live Cash filter to your threshold, for example under 12 months of runway, then add a Trial Phase or Completion Date filter. The screener returns companies that have a near-term catalyst and limited cash, a common setup for financing or dilution risk ahead of the event.
What is PTRS (probability of technical and regulatory success)?
PTRS estimates the probability that a drug candidate succeeds technically and wins regulatory approval, based on its phase, indication, and trial design. Catalyst Sync lets you filter and rank catalysts by PTRS so you can focus on higher or lower probability events.
What types of biotech catalysts can I screen?
Clinical trial data readouts, trial completions and status changes, phase transitions, and regulatory events such as FDA decisions and advisory committee meetings, across oncology, CNS, immunology, rare disease, and 35 therapeutic areas.
How is this different from an FDA or PDUFA calendar?
An FDA or PDUFA calendar lists regulatory decision dates so you can browse by date. Catalyst Sync is a screener: it filters the entire catalyst universe by financials such as cash runway and burn rate, approval odds (PTRS), trial phase, and FDA designation to surface the catalysts that match your criteria. For a specific FDA decision date, use the FDA calendar.
How often is the catalyst data updated?
Catalyst Sync updates daily from clinical trial registries, SEC filings, and FDA sources, covering 83,000+ tracked clinical trials.